autoimmune diseases

News

Shine rubs off Argenx after Vyvgart Hytrulo fails trial

Argenx has been riding high of late thanks to buoyant sales growth for its Vyvgart therapy for muscle-wasting disease generalised myasthenia gravis (gMG), but a failed pha

News

UCB on course for approval of gMG drug Rystiggo in EU

UCB’s efforts to build a franchise of therapies for muscle-wasting disease generalised myasthenia gravis have taken another step forwards after the CHMP recommended approv

News

Abcuro raises $155m for KLRG1 drug trial

Abcuro has raised $155 million in an oversubscribed second financing round that will fund its phase 2/3 trial of lead drug ABC008 for the treatment of inclusion body myosi

News